QUEBEC CITY, May 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS; TSX: AEZ) (the "Company"), announced today that it has entered
into an "At Market" Issuance ("ATM") Sales Agreement, dated May 21,
2013, with MLV & Co. LLC ("MLV"), under which the Company may, at its
discretion, from time to time during the term of the sales agreement,
sell up to a maximum of 2.5 million of its common shares through ATM
issuances on the NASDAQ Stock Market up to an aggregate amount of
US$4.6 million. MLV will act as sales agent for any sales made under
the ATM. The common shares will be sold at market prices prevailing at
the time of the sale of common shares, and, as a result, prices may
vary.
In connection with the execution of the ATM Sales Agreement with MLV,
the Company will file shortly a prospectus supplement to its U.S. shelf
prospectus, dated June 8, 2012, forming part of its U.S. registration
statement on Form F-10 with the United States Securities and Exchange
Commission ("SEC") as well as a prospectus supplement to its Canadian
final base shelf prospectus dated June 8, 2012.
The U.S. shelf prospectus and, when filed, the supplement thereto, will
be available on the SEC's website (www.sec.gov) and the Canadian final base shelf prospectus and, when filed, the
supplement thereto, will be available on the SEDAR website maintained
by the Canadian Securities Administrators at www.sedar.com. Alternatively, MLV will provide copies of the U.S. documents upon
request by contacting MLV & Co. LLC, Attention: Randy Billhardt, 1251
Avenue of the Americas, 41st Floor, New York, NY 10020, or by calling 212-542-5882, while copies of
the Canadian documents may be obtained by contacting the Company's
Investor Relations department directly by calling (418) 652-8525, ext.
265.
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy any of the common shares, nor shall
there be any sale of the common shares in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state
or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.